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and the CNOM for review. A few modifications may be made for
the final version. The rules of good practices may also be updated
so as to take into account any changes in regulations as well as
working group conclusions on access to nominative medical
records to be composed at the request of the French Hospital
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phone d’information me´dicale [SOFIME], President Gabriel
Nisand) has requested to be included. Further work seems
necessary to draw up a guide to good practices on the production
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safety); PMSI, Programme de me´dicalisation du syste`me d’information (Patient
Care Classification System); RHA, re´sume´ hebdomadaire anonyme (weekly
anonymous summary); RSA, re´sume´ de sortie anonyme (anonymous discharge
summary); RSS, re´sume´ standardise´ de sortie (standardized discharge summary);
TEC, technicien d’e´tude clinique (clinical study technician); TIM, technicien
d’information me´dicale (medical information technician).
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Preface
This document is the result of the reflection of a working
group whose participants included members of the colleges of
professors of biostatistics, medical informatics, and public
health (CIMES and CUESP), the National College of Medical
Information (Colle`ge national de l’information me´dicale
[CNIM]), the Advisory Board on Medical Research Data
Processing (Comite´ consultatif sur le traitement de l’informa-
tion en matie`re de recherche dans le domaine de la sante´
[CCTIRS]), and the French Personal Data Protection Authority
(Commission nationale informatique et liberte´s [CNIL]).
This group was created in response to the growing demand
for secondary use of medical records, notably with the Medical
Information Departments (de´partements d’information me´di-
cale [DIM]), which occupy a strategic position as directors of
medical data analysis and guarantors of the privacy of medical
records in healthcare institutions.
The group’s objective was to propose rules of good practice
for the secondary use of patient medical records aimed at DIMs,
researchers, and healthcare institutions.
The rules drawn up concern studies using heath data
collected previously during healthcare procedures or for
medical-economic purposes. They include data access condi-
tions, regulatory procedures, the healthcare providers autho-
rized to have access, and procedures for informing the patient.
These rules have no binding legal value. They comprise a
review of the procedure so that medical records collected within
healthcare institutions can be used with full respect of the
regulations.
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Today it is emerging that the data collected in healthcare
institutions for patient care or in medical-economic databases
(Patient care classification system; programme de me´dicalisa-
tion des syste`mes d’informatione´ [PMSI]) hold major potential
for clinical and epidemiological research, vigilance programs,
care quality and medical practices assessment, and public
health in general. Crossing clinical and genomic databases is
becoming imperative in biomedical research.
The patients’ electronic medical records are being extended
to healthcare institutions, facilitating data access by making
data more readily available and easier to use directly.
Biomedical data warehouses are being set up, as are
warehouses of medical-economic data, supplied from hospital
information systems. They make it possible, for example, to
examine the feasibility of a study, to create patient cohorts, and
they can be the basis for production of health indicators or for
the institution’s management indicators.The requests for access to healthcare institutions’ medical
files are growing, by both internal and external organizations.
We can cite the IPAQSS (Indicateurs pour l’ame´lioration de la
qualite´ et de la se´curite´, indicators for improving quality and
safety) audits, the evaluation of care within a network, the
surveys of institutions by external companies, the prescreening
phases in clinical research, the multicenter evaluation of
healthcare practices, and the validation of data collection by
researchers external to the institution. Similarly, DIMs are
increasingly solicited to transmit PMSI data (audits, registries,
assessment studies, indicator production).
It should be emphasized that the secondary use of medical
records outside the care setting changes the finality of the data
analysis compared to the context in which these data were
collected: they were initially collected for the medical management
of individuals. Setting up electronic medical records in a healthcare
institution requires a declaration with the French Personal Data
Protection Authority (Commission nationale informatique et
liberte´s [CNIL]). From that moment on, any use for purposes
other than the care and follow-up of these individuals requires a new
procedure within the CNIL aimed at declaring this new purpose.
Although for biomedical research2 or prospective epidemiological
research, the procedures seem to bewell known3, guidance for other
uses deserves  to be specified more clearly.
The guide does not include the situations covered by
regulations such as external inspection or accreditation visits.
Two cases are differentiated:
 access to personal medical records within the institution by
the institution’s health professionals without these data being
communicated outside the institution;
 access to personal medical records within the institution by
health professionals outside the institution or communication
of these data outside the institution.
In each case, the health professionals who may make a
request for access to data are specified, as are examples of
practical situations encountered, the rules for good practice, a
review on informing the patient, and the formal procedures to
carry out with the CNIL by those requesting data.
Decisional trees are provided in the appendix.
2. Case 1 – Access to personal medical records within
the institution by the institution’s health professionals
with no communication of data outside the institution
2.1. Professionals concerned
 Member of the senior healthcare team4 or in training, notably
physician, intern, midwife, midwife student, head nurse,
nurse, or nursing student;
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supervisor from the institution, for example, an MD,
midwife, or head nurse;
 non-members of the healthcare team within the framework of
their missions, e.g., DIM physician, clinical research
associate (ARC), clinical study technician (TEC), medical
information technician (TIM), quality engineers, and risk-
management engineer under the responsibility of a physician
with authorized access to medical records.
2.2. Practical situations
 Healthcare safety audit (e.g., verification of the operating
room check-list in the patient file, identification of surgical
site infections);
 doctoral and master’s theses;
 single-center research project on previously collected data
(same group of institutions);
 evaluation of practices;
 pharmacoepidemiology (it may be necessary to contact the
patient at a later date);
 feasibility study (before setting up a project, the researcher
wishes to verify that a sufficient number of patients is
available);
 setting up a cohort: data-based retrospective research;
 prescreening: for therapeutic trials or setting up a cohort or
identifying cases may involve contacting the patient at a later
date;
 development of decision-support systems (e.g., identification
of adverse effects of medications, surgical site infections).
2.3. Good practice rules
Access to personal medical records should only be granted
under the responsibility of a physician of the institution
authorized to provide such access to patient files, either
professionally through his or her caregiver relation with the
patient or institutionally through the mission entrusted him or her
by the institution. An agreement to respect professional secrecy
should be signed if access is granted to a non-health professional.
A personal data access and proper use charter should be
drawn up by the institution and is brought to the attention of
health professionals (see a model in Appendix D).
A validation commission for access to personal medical
records can be created in the institution (from the medical
board, for example).
The nominative list of patients whose medical records will
be used cannot leave the institution. This list can be used as a
table of correspondence (patient identity and study number).
Depending on the local organizations, this list should be
preserved by the DIM physician, the archives, or the
supervising physician in his or her department. This list
should only be circulated in accordance with article 34 of the
information technology and civil liberties law.
The DIM physician must be notified of how the PMSI
hospitalization data will be used and how the PMSI databases
will be searched.The responsibility of cross-searching the institution’s
medical databases lies with the DIM physician, who delivers
the authorizations to those concerned.
The traceability of requests for access to patient files is
guaranteed.
Access to data is accorded for the time of the study.
Whenever possible, it is recommended to only give access to
anonymous or deidentified data.
Access to or communication of anonymous data does not
require the patient’s agreement, but the research project must be
validated.
Patients’ refusals to use their medical records are recorded in
the medical file and when the file is computerized in the
institution’s data system. A separate refusal file should not be
created.
If it is necessary to contact patients, only those who have not
refused will be contacted.
The patient will be contacted by the clinician responsible for
the department that cared for the patient or a member of the
team under the responsibility of said clinician.
2.4. Informing the patient
Patients should be provided clear and honest information by
their caregivers. A notice included in the patient handbook or
given to patients during a consultation informs them of the
secondary use of their medical records and access to their
medical records (see model, Appendix C).
Information will also be posted in waiting rooms as well as
on the institution’s web site.
With the exception of mandatory studies, determined by
legislative or regulatory provision, patients are entitled to
discretionary refusal concerning access to their individual
medical records.
A form is provided for patients refusing to be contacted.
When contacted, patients are informed of the data that may
already have been collected from their medical records.
Use of institutions’ medical and medical-administrative
databases resulting in the production of aggregated indicators
(with at least 10 subjects) is not subjected to patient agreement.
Access to anonymous data by the institution’s health
professionals is not subjected to patient agreement.
The list of the studies for which personal medical records are
used will be available on the institution’s web site.
Crossing clinical data with data from the Biological
Resources Center (Centre de ressources biologiques) should
respect the regulations as regards collection of biological
materials, which assumes written consent by the patient for
secondary use of samples for research purposes. This regulation
also applies to genetic data and genetic samples linked to
identifying information.
2.5. CNIL formalities
See Appendix B for details of specific situations.
The statistical use of computerized patient records by the
institution in possession of data must be declared to the CNIL
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This is done through the data and liberties correspondent
(correspondant informatique et liberte´s [CIL]) for the
institutions where this is in place.
If the party requesting access is creating a personal data file,
this party will initialize the CNIL declaration, with the person
responsible for data analysis being the representative of the
organization (e.g., director of the healthcare institution).
A declaration is made for every end-use of a file created.
Implementation of new analysis on this file with the same end-
use on the same data categories does not require a new
declaration. However, any modifications should be declared to
the CNIL (notably recipients, new categories of data).
Statistical analysis based on databases of PMSI hospitaliza-
tion summaries that are internal to the institution must be
declared to the CNIL either during the initial declaration of
PMSI analysis or by an amendment letter.
Authorization for use of regional or national PMSI databases
(RSA, RHA, etc.) by institutions must be requested, as
stipulated in the relevant texts of chapter X6, with the CNIL. If
the institution is conducting several studies responding to the
same end-use on identical data with identical recipients, the
institution can request a single authorization from the CNIL. It
should detail the list of projected analyses.
Studies leading to production of aggregated results (e.g.,
feasibility study) with no access to individual data do not
require a declaration with the CNIL. It is nevertheless advisable
to ensure the absence of patient identification, most particularly
when rare diseases are concerned.
3. Case 2 – Access to personal medical records within
the institution by health professionals not within the
institution or communication of individual medical




 non-health professionals, e.g., clinical research associate
(attache´ de recherche clinique [ARC]), clinical study
technician (technicien d’e´tude clinique [TEC]), quality
engineer, risk-management engineer under the responsibility
of a physician with authorized access to medical records.




 structure with a public health mission;
 promoter of clinical trial or other health study (observational,
epidemiological, etc.);
 consulting firm.5 See the Glossary.
6 Personal health data analysis for purposes of evaluation or analysis of
healthcare and preventive practices and procedures.3.3. Practical situations
 Multicenter research projects or projects designed to assess
practices;
 assessment of practices within the healthcare network
context, by an organization with a public health mission or
by an external firm:
 data collection by the institution’s professionals, transmis-
sion of questionnaires to the project head,
 data collection by external TECs,
 communication of data extracted from the institution’s
PMSI file,
 access to the medical records through external ARCs or
TECs to verify data transmitted (quality control of
assessment or epidemiological studies),
 communication of parts of medical records;
 research survey requiring contacting patients:
 patient satisfaction survey,
 prescreening to establish a multicenter cohort,
 audit to optimize coding of PMSI hospitalization reports by
an external firm,
 development of decision-support system.
3.4. Good practice rules
Access to personal medical data or their communication is
only possible if the analysis has received prior authorization by
the CNIL (see Appendix B).
The institution will set up a validation committee for access
to personal medical records.
The requesting party should be able to explain its request and
provide the authorization delivered by the CNIL. The institution
can make use of a form letter listing the documents to be provided
by the organization requesting data be transmitted. Formalizing
the exchanges and commitments with the requesting party
ensures a safer legal framework. The requesting party guarantees
that the data transmitted are in accordance with the data declared
with the CNIL for analysis and also guarantees having set up a
procedure for informing patients and managing refusals or
having obtained a special dispensation to the CNIL’s information
technology and civil liberties law.
Access to personal medical data by a person external to the
institution or their communication to another organization is
granted under the responsibility of a physician from the
institution authorized to access the patient’s file, either
professionally through his or her caregiver relation with the
patient or institutionally through the mission entrusted him or
her by the institution.
Medical records are accessed within the institution. An
agreement to respect professional secrecy should be signed by
professionals outside the institution. A personal data access and
proper use charter should be drawn up by the institution and is
brought to the attention of health professionals (see a model in
Appendix D).
Whenever possible, it is recommended to give access only to
anonymous or deidentified data.
When data from the PMSI standardized discharge summary
is requested, a DIM physician should be associated starting at
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feasibility of its implementation in the institutions concerned.
The request will be treated under the responsibility of the DIM
physician of each institution.
The institution’s medical databases will be searched by the
DIM physician or under his or her responsibility.
Access to individual personal medical records under the
responsibility of a physician of the institution is possible during
quality control or case validation by the organization
responsible for a medical research project in which the
institution is collaborating.
The research organization will have specified the need to
access personal medical records in its request for authorization
with the CNIL.
The retrospective collection of data from the patient records
by a professional external to the institution should be authorized
by the CNIL. In this case, the authorization will be based on
chapter IX of the modified law of 6 January. The request
submitted to the CNIL should describe the data access modalities
and explain the request for special dispensation to informing the
individual patient; access by ARCs and TECs within the limits of
their missions will be specified therein. The request for special
dispensation to the obligation to inform the individual can be
found in the authorization delivered by the CNIL.
The prescreening phase of clinical trials or epidemiological
studies is carried out by the institution’s ARCs and TECs under
the responsibility of an accredited physician within the
institution, with ARCs made available by the Cengeps subject
to a contract with the institution.
Following the prescreening phase, if patients must be
contacted, only those patients who have not previously refused
can be contacted. The patient will be contacted by the clinician
responsible for the department that cared for the patient or a
member of the team under the responsibility of said clinician.
Except in cases of exceptional dispensation, identification
data are removed or blinded at the time of data transmission.
Access to or communication of indirectly nominative data
does not always require the patient’s individual agreement; the
research project must, however, be validated scientifically and
the researcher commits to not attempting to reidentify the patient.
If the type of data used (whether or not it is indirectly
nominative) is questioned, the opinion of the DIM or the data
access validation commission may be solicited.
Aggregate health data will be communicated under the
responsibility of a physician of the accredited institution. It
must be ensured that patients cannot be identified (with at least
10 subjects in the study).
3.5. Exceptional cases
3.5.1. Communication of medical records to registries
In France, registries respond to a precise definition7.
Healthcare institutions are authorized to transmit nominative7 Decree of 6 November, modified, relative to the National Committee of
Registries.data crossed with PMSI files that have CNIL authorization for
this. Recommendations were issued by the CNIL in 20038 for
the implementation of cancer registries. This could be reviewed
and extended to all registries. Work is currently underway
within the CNIL so that this recommendation is revised.
3.5.2. Access to RSS or RSA files by consulting firms
A priori, RSS (re´sume´ standardise´ de sortie, standardized
discharge summaries) files cannot be communicated to persons
who do not belong to the DIM. The institution can decide to
relegate the coding or an audit of the coding to a DIM physician
in another institution in conditions adhering to article L. 6113-7
of the Public Health Code within the framework of a contract.
If an external firm processes the RSA (re´sume´ de sortie
anonyme, anonymous discharge summary) file, an authorization
from the CNIL must be obtained. A contract must be signed, the
firm undertakes to destroy the file after data analysis or to return it
to the institution. The DIM physician is advised of this contract.
3.6. Informing the patient
A notice included in the patient handbook or given to
patients during a consultation informs them of the use of their
medical record and their right to refuse.
If the data for which access or communication are requested
are directly nominative or coded with a table of correspon-
dence, the patient must have been informed individually or a
special dispensation from the CNIL information technology
and civil liberties law is required, and the patient must not have
indicated his or her right to refuse secondary use of his or her
medical records.
In absence of a special dispensation from the information
technology and civil liberties law, the project head or the
investigators are required to set up the procedure for informing
the patient. The notice to provide to the patient is therefore
specific to each study.
The research organization can also provide the institution
with an information notice.
In addition, assuming that the request involves access to
personal data of patients present in the institution, the written
forms must be accompanied by clear and honest verbal
information allowing the patient to legitimately exercise his or
her right to refuse.
For registries, general information on registries can be found
in the institution’s patient handbook, on the institution’s web
site, or is posted in the hospital departments.
In addition, the law on data and liberties stipulates that
persons concerned should be informed individually. This is the
case for all studies that come under chapter IX of the law
(health research), also applicable to registries.
Patients are entitled to discretionary refusal of access to their
medical records, except when this access is allowed by8 Deliberation No. 03-053n, 27 November 2003 on the adoption of recom-
mendations concerning personal data analysis implemented by cancer regis-
tries.
Data analysis internal to the institution with no external communication
Data Nominative or
indirectly nominative





Normal declaration No declaration subject
to declaration of statistical
analysis in declaration of






Patient right to refusal
Information note included
with patient handbook
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insurance system validation).
Use of institutions’ medical and medical-administrative
databases resulting in the production of aggregated indicators is
not subject to patient agreement (see CNIL formalities above).
Transmission of aggregated or anonymous data or access to
anonymous data without access to the medical records is not
subject to patient agreement. Particular precautions should
nonetheless be taken so that the patient cannot be identified
(e.g., rare diseases).
The list of the studies for which personal medical records are
used will be available on the institution’s web site.
Analysis of genetic data requires the express and prior
consent of the persons involved.
3.7. CNIL formalities
The requesting party must show proof of its request with the
CNIL (see Appendix B).
General principles:
 the requesting party responsible for a study requiring
communication of personal medical records must have
CNIL authorization:
 chapter IX9 (CCTIRS and CNIL) if there is access to the
medical file or if the data communicated are identifying;
 chapter X if the data communicated are indirectly
nominative with no return to patient files. This is also
the case if the study includes a request for access to the
SNIIRAM10 (with or without the PMSI database).
This also applies to communication of data from the
institution’s PMSI databases of hospitalization summaries.
Transmission of RSA-type data or data that is indirectly
nominative comes under chapter X. Failing this, the study
comes under chapter IX.9 Analysis of personal data for research purposes in the healthcare sector.
10 Under this assumption, notification of the l’Institut des donne´es de sante´
(Institute of Health Data) is also required.Acknowledgements
We wish to thank Ms. De´lia Rahal-Lo¨fskog of the French
Personal Data Protection Authority (Commission nationale
informatique et liberte´s) for her availability and her assistance on
the legal texts, most particularly on personal data protection, Dr.
Jacques Lucas, Vice-President of the French Medical Council
(Conseil national de l’Ordre des me´decins), and Dr. Jean-Marie
Faroudja, President of the Ethics and Deontology section, for
their attentive reading and comments as well as the Privacy
Commission of the SOFIME for its comments.
Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at http://dx.doi.org/10.1016/
j.respe.2014.03.005.
Appendix B. Procedure for implementation of personal
health data analysis requiring secondary use of
previously collected data for healthcare or medical-
economic purposes
Data analysis with communication of data outside the institution
Data
Nominative indirec tly nominative ag gregated (n 10) or anon ymou s
or co ded with with no follow-up or indirec tly nominative2
tab le of correspondence wit h no access t o nomin ative  da ta3
(e.g., lon gitudinal follow-up)  Access  to nominative da ta
(e.g., pa tien t file)
Yes No
CNIL proced ure
Promotor Authoriz ation Authoriz ation Authoriz ation Authoriz ation
Chap. IX Chap. IX Chap. IX Chap. X
Informing
Patient
Requ est ing part y Individua l information Individua l information and spec ial dispen sation  for
and right to refuse or right to refuse individual da ta to reque st
consent1 or from CNIL
spec ial dispen sation  for
individual information 
to requ est fr om CNIL 
if imposs ible to inform pa tien t
Inst itution Gene ral informationa l notice General informational not ice Gene ral informationa l notice Gene ral informationa l notice
with pa tient  handboo k with pa tient  handboo k with pa tient  handboo k with pa tient  handboo k
Patien t’s right t o refuse Patien t’s right t o refuse Patien t’s right t o refuse
1 if data shared between institutions, the patient’s writt en co nsent is required
2 probability of identifying the patient is low
3 the  case of access  to no mina tive da ta remains t o be  clarified, no tab ly in terms  of of the  da ta and the  pa tient’ s righ t to refuse
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institutions’ secondary use of medical records
The data in your medical records may be used for research
purposes. In all circumstances, only those individuals subject to
professional secrecy can access these data under the
responsibility of a physician from the institution.
In accordance with the provisions of the information
technology and civil liberties law, these studies are declared
with the CNIL, only coded data respecting patient privacy are
analyzed, with no mention of patient family or given names,
and the results are produced in an aggregated form making it
impossible to identify you.
You may also be contacted by the department responsible for
your care should they wish you to participate in a new study.
In all circumstances and in accordance with the information
technology and civil liberties law (law of 6 January 1978,
modified), you have the right to access and rectify your data. At
any time you can refuse to have the data in your medical records
used or to be contacted, as long as the data analysis is not
subject to a legal obligation, without having to justify your
refusal. Exercising your right to refuse will have no
consequence on your care or the quality of your relation with
the medical teams. You can also refuse to be contacted to
participate in a new study.To exercise your rights you can contact
. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .. . .
Appendix D. Model of a charter giving access to the
institution’s medical records when used outside the
healthcare setting
1. Subject
The present charter defines the rules to be observed during
access to and analysis of medical records as well as the
obligations beholden to users concerning data security.
2. Scope of application
a. Access by professionals of the institution for studies
conducted by the institution:
i. Subject to the signature of a commitment to respecting
professional secrecy for non-healthcare professionals.
b. Access for multicenter studies under the following
conditions:
i. A copy of the authorization delivered by the CNIL
provided;
ii. Agreement to respect the CNIL authorization (data
collected, personnel collecting data, recipients,
informing patients);
iii. Agreement to respect professional secrecy signed by
the person accessing the data if said person is external
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within the institution.
3. Responsibilities
Medical records are accessed by or under the responsi-
bility of a physician authorized to access the patient records
(indicate physician’s name and position).
The professional agrees to:
- respect the confidentiality of the data;
- access only the data necessary for the study;
- make no copies of and not remove nominative data or
documents from the institution, including tables of
correspondence unless there is a specific arrangement
with the CNIL: in this case the nominative data are
preserved in a file separate from the medical records;
- protect the files created (indirectly nominative data) and
destroy them after publication of the results.
4. Organization of access to data
The institution shall describe the procedure for collecting
data or agreement of the physicians caring for the patients
concerned by the study.
The institution can draw up a request form specifying:
- the study’s project leader;
- the study’s subject and protocol;
- the data that the requesting party wishes to access;
- the study’s CNIL authorization number;
- the authorizations requested (CPP, Committee for the
Protection of Persons; ethics committee; the department
head or pole director);
- the nominative list of the professionals who can access data
during the study;
- the access period.
It will specify the modalities of opening and closure of
access.
5. Sanctions
The failure to respect the legal dispositions and the
principles established or reviewed by the charter entails the
personal responsibility of the user.
Unauthorized access to confidential data is punishable by
1 year imprisonment and a 15,000-euro fine (CSP article
l110-4).
Breach of the information technology and civil liberties
law is punishable by 5 years’ imprisonment and a 300,000-
euro fine (Penal Code, articles 226-16 to 226-21).I, the undersigned, . . .. . .. . .. . .. . ., hereby certify that I have




Personal or identifying data: Any data relative to a natural person, identified or
identifiable, directly or indirectly, by reference to an identification number
or one or several elements that are specific to him or her (article 2,
information technology and civil liberties, CNIL glossary). Example of
indirectly nominative data: file with no indication of individuals’ identity
replaced with a number allowing retrieval of identity through a table of
correspondence. This guide concerns all medical records on patients
collected in the healthcare institution, including standardized discharge
summaries.
Analysis of personal data: Any operation or any group of operations involving
such data, whatever process may be used (article 2, information technology
and civil liberties law)
Single-center research: Study conducted by the institution within said institu-
tion and for its own account (the institution is the promoter of said study and
is responsible for data analysis)
Making data anonymous: Process applied to data ensuring that the patient can
no longer be identified directly or indirectly
Deidentification: Removal of identifiers (list of data categories defined as the
patient identification numbers or hospitalization numbers, dates, family
names, given names, addresses, patients’ or institutions’ telephone numbers,
city or postal codes, etc.)
Anonymous data: Data that does not allow direct or indirect identification of a
natural person even when grouped.
Feasibility study: First phase of clinical trial development, before submission
of the CNIL file, the purpose of which is to determine the number of
potential subjects for a study and to identify the populations of interest that
may be included in the trial. This definition may be extended to the
preparatory phase of a health research protocol in view of putting together
a patient cohort.
Prescreening: During a declared clinical trial, the phase preceding patient
contact, based on the institution’s medical records and/or PMSI databases,
consisting in searching for patients responding to the trial’s criteria. This
definition may be extended to drawing up a cohort for a health research
project. This phase differs from the screening phase, which is conducted
once the patient has been contacted and has granted consent to participate in
said research; the inclusion criteria are verified and/or completed at this
time.
Registry: A registry is defined as a continuous and exhaustive collection of
nominative data involving one or several health events in a geographically
defined population, for research or public health purposes, by a team
possessing the appropriate skills.
